WPRIM Management System> DCMS> Blood Research> 2020> 55

Volume: 55

1. Bone marrow involvement by primary oxalosis Page:192—192
2. COVID-19 in a patient with chronic myelomonocytic leukemia: a twisting tale Page:278—281
3. Outcomes of patients with essential thrombocythemia and unnoticed thrombocytosis prior to diagnosis Page:281—282
4. Pulmonary embolism rate in patients infected with SARS-CoV-2 Page:275—278
5. The detection of Howell-Jolly body-like inclusions in a case of coronavirus disease-2019 (COVID-19) Page:191—191
6. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey Page:206—212
7. Prognostic value of TNF-α-308 and IFN-γ-874 single nucleotide polymorphisms and their plasma levels in patients with aplastic anemia Page:193—199
8. Mining of mortality-related findings in rare bleeding disorders:a retrospective study from two centers Page:213—216
9. Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes Page:200—205
10. Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era Page:217—224
11. Changing the frequency and spectra of chromosomal aberrations in Korean patients with acute leukemia in a tertiary care hospital Page:225—245
12. First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients Page:253—261
13. Safety and effectiveness of Rixubis in patients with hemophilia B:a real-world, prospective, postmarketing surveillance study in South Korea Page:246—252
14. Long-term treatment outcomes of children and adolescents with lymphoblastic lymphoma treated with various regimens:a single-center analysis Page:262—274
15. Classification of acute myeloid leukemia Page:S1—S4
16. New agents in acute myeloid leukemia (AML) Page:S14—S18
17. AL amyloidosis: advances in diagnosis and management Page:S54—S57
18. Extranodal NK/T cell lymphoma Page:S63—S71
19. Recent advances in chronic lymphocytic leukemia therapy Page:S72—S82
20. Treatments for children and adolescents with AML Page:S5—S13
21. Recent advances in the management of primary central nervous system lymphoma Page:S58—S62
22. Treatment of relapsed and refractory multiple myeloma Page:S43—S53
23. Optimal therapy for adolescents and young adults with acute lymphoblastic leukemia-current perspectives Page:S27—S31
24. Frontline therapy for newly diagnosed patients with multiple myeloma Page:S37—S42
25. Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation Page:S19—S26
26. Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia Page:S32—S36
27. Chronicles of blood morphology associated with steroid use Page:128—128
28. An interesting story of a clone Page:115—117
29. Response of multifocal acquired demyelinating sensorimotor neuropathy associated with atypical chronic lymphocytic leukemia to rituximab therapy Page:117—120
30. Adult T-cell leukemia/lymphoma and Glucose-6-phosphate dehydrogenase deficiency rapidly diagnosed through blood smear examination Page:76—76
31. Large granular lymphocytes (LGL) in primary Sjögren syndrome (pSS): immunophenotype and review on the pathological role of T cells in pSS Page:120—123
32. Lineage switch from B lymphoblastic leukemia with KMT2A-rearranged to mixed-phenotype acute leukemia under daratumumab Page:75—75
33. Chronic phase of chronic myeloid leukemia presenting with myeloid sarcoma in an adolescent Page:112—115
34. Atypical presentation of hairy cell leukemia: a report and comprehensive review Page:123—127
35. Coronavirus disease-19 and its hematological manifestations Page:71—74
36. Impact of using genotyping to predict SERF negative phenotype in Thai blood donor populations Page:107—111
37. Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study Page:85—90
38. Natural soluble human leukocyte antigen class I in donor serum neutralizes donor-specific HLA alloantibodies in recipient serum Page:91—98
39. Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients Page:77—84
40. Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma Page:99—106
41. Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how? Page:67—68
42. Response to the letter by Langabeer on “Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria” Page:68—68
43. Helicobacter pylori testing in a population of Korean patients with pernicious anemia Page:69—69
44. Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation Page:62—65
45. Daratumumab in dialysis-dependent multiple myeloma Page:65—67
46. Bibliometric analysis of studies about acute myeloid leukemia conducted globally from 1999 to 2018 Page:1—9
47. Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience Page:57—61
48. Characteristics of DNMT3A mutations in acute myeloid leukemia Page:17—26
49. A general view of CD33⁺ leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy Page:10—16
50. Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells Page:35—43
51. Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome Page:27—34
52. Thromboprophylaxis after bariatric surgery Page:44—48
53. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases Page:49—56
54. Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression Page:175—177
55. Identifying the link between multiple myeloma and neurofibromatosis type I Page:187—189
56. An illustrative case of B-cell prolymphocytic leukemia Page:181—184
57. Nuances in the management of acquired hemophilia A in an elderly patient with large granular lymphocytic leukemia Page:180—181
58. Acute myeloid leukemia with myelodysplasia-related changes and basophilic differentiation Page:130—130
59. Peripheral blood histoplasmosis in an immunocompetent child with disseminated disease Page:129—129
60. Hb-M Hyde Park: a rare cause of cyanosis arising from a de novo mutation Page:177—180
61. Rapid resolution of bone marrow necrosis mimicking relapse of pediatric acute lymphoblastic leukemia Page:184—187
62. Utility of screening tools to differentiate beta thalassemia trait and iron-deficiency anemia - do they serve a purpose in blood donors? Page:169—174
63. Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression Page:131—138
64. Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population Page:146—150
65. KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute Page:159—168
66. Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation Page:151—158
67. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study Page:139—145